PMID- 37263073
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20230801
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 131
DP  - 2023 Aug
TI  - Elevated expression of interleukin 16 in chronic lymphocytic leukemia is 
      associated with disease burden and abnormal immune microenvironment.
PG  - 107315
LID - S0145-2126(23)00580-5 [pii]
LID - 10.1016/j.leukres.2023.107315 [doi]
AB  - Interleukin-16 (IL-16) is a novel biomarker that has been implicated in many 
      cancers as well as inflammatory diseases. In this study, we examined plasma 
      levels of 30 cytokines and chemokines in chronic lymphocytic leukemia (CLL) and 
      monoclonal B cell lymphocytosis (MBL) patients, and examined their association 
      with disease stage, CLL biomarkers and T cell subsets. Interleukin 16 (IL-16) was 
      identified as a relatively uncharacterized cytokine significantly elevated in CLL 
      patients compared to healthy controls and MBL patients. Plasma levels of IL-16 
      were significantly elevated by Rai stage 0, increased by Rai stage 3-4, 
      correlated strongly with lymphocyte count and were decreased after Ibrutinib 
      treatment. CLL cells expressed IL-16 mRNA and spontaneously secreted IL-16 in 
      vitro. CLL cells express IL-16 mRNA at significantly higher levels in lymphoid 
      tissues than blood, and we observed that IL-16 release was increased in 
      co-cultures of CLL and autologous CD4 + T cells. Elevated plasma IL-16 levels 
      were associated with abnormalities in the immune microenvironment including 
      multiple inflammatory cytokines and chemokines and expansion of type 1 follicular 
      helper T cells. Taken together, our results identify IL-16 as a novel biomarker 
      in CLL with potential functional roles in cellular interactions between CLL cells 
      and T cells.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Wu, Xun
AU  - Wu X
AD  - Department of Immunology, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada.
FAU - Thisdelle, Jordan
AU  - Thisdelle J
AD  - Department of Immunology, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada.
FAU - Hou, Sen
AU  - Hou S
AD  - Department of Immunology, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada.
FAU - Fajardo-Despaigne, J Ernesto
AU  - Fajardo-Despaigne JE
AD  - Department of Immunology, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada.
FAU - Gibson, Spencer B
AU  - Gibson SB
AD  - Department of Immunology, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada; Department of Biochemistry and Medical Genetics, 
      Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; 
      CancerCare Manitoba Research Institute, Winnipeg, MB, Canada.
FAU - Johnston, James B
AU  - Johnston JB
AD  - Department of Internal Medicine, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada; CancerCare Manitoba Research Institute, Winnipeg, 
      MB, Canada.
FAU - Dawe, David E
AU  - Dawe DE
AD  - Department of Internal Medicine, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada; CancerCare Manitoba Research Institute, Winnipeg, 
      MB, Canada.
FAU - Banerji, Versha
AU  - Banerji V
AD  - Department of Internal Medicine, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada; CancerCare Manitoba Research Institute, Winnipeg, 
      MB, Canada.
FAU - Marshall, Aaron J
AU  - Marshall AJ
AD  - Department of Immunology, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada; Department of Internal Medicine, Rady Faculty of 
      Health Sciences, University of Manitoba, Winnipeg, MB, Canada; Department of 
      Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of 
      Manitoba, Winnipeg, MB, Canada; CancerCare Manitoba Research Institute, Winnipeg, 
      MB, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230518
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Interleukin-16)
SB  - IM
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/therapy
MH  - Interleukin-16
MH  - Lymphocyte Count
MH  - *Lymphocytosis
MH  - Cost of Illness
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Chemokine
OT  - Chronic lymphocytic leukemia
OT  - Cytokine
OT  - Follicular helper T cells
OT  - Interleukin-16
OT  - Monoclonal B cell lymphocytosis
COIS- Declaration of Competing Interest The authors have no conflicts of interest to 
      disclose.
EDAT- 2023/06/02 01:07
MHDA- 2023/08/01 06:45
CRDT- 2023/06/01 18:06
PHST- 2023/01/18 00:00 [received]
PHST- 2023/05/10 00:00 [revised]
PHST- 2023/05/16 00:00 [accepted]
PHST- 2023/08/01 06:45 [medline]
PHST- 2023/06/02 01:07 [pubmed]
PHST- 2023/06/01 18:06 [entrez]
AID - S0145-2126(23)00580-5 [pii]
AID - 10.1016/j.leukres.2023.107315 [doi]
PST - ppublish
SO  - Leuk Res. 2023 Aug;131:107315. doi: 10.1016/j.leukres.2023.107315. Epub 2023 May 
      18.